European Commission offers €2 million prize for a leap forward in vaccine technology
Brussels, 16 April 2012
The European Commission today offered a €2 million prize to encourage inventors to overcome one of the biggest barriers to using vaccines in developing countries: the need to keep them stable at any ambient temperature. The prize was announced by Research, Innovation and Science Commissioner Máire Geoghegan-Quinn at the third Innovation in Healthcare conference in Brussels. It is the first time the European Commission has offered a so-called inducement prize to stimulate research and innovation in the European Union.
Research, Innovation and Science Commissioner Máire Geoghegan-Quinn said: "Many people in tropical and developing countries cannot benefit from life-saving vaccines as these vaccines are damaged before they can reach them. The goal of this prize is to galvanise scientists into producing innovations which can solve this global health problem".
Most Europeans are protected from infectious diseases such as hepatitis B and measles thanks to widespread use of vaccination, but many people in tropical and developing countries cannot benefit from these great achievements of medicine. Vaccines are often rendered ineffective by temperature variations in these regions during transport and storage, long before they can be administered. The WHO estimates that half of all supplied vaccine doses are wasted, mostly due to an inadequate "cold chain" to protect them before use.
The use of prizes as a mechanism to induce innovation has a long history. Things we now take for granted such as transatlantic flights, tinned food and navigation at sea were all encouraged by competitions to win prizes. The use of prizes to encourage scientific breakthroughs could be expanded under Horizon 2020, the EU's funding programme for research and innovation after 2014.
Frequently asked questions on the European Commission's vaccine technology prize
What are inducement prizes?
Inducement prizes refer to a funding scheme where first a technological, social or scientific challenge is defined and an award promised for the delivered breakthrough solution. The concept of prizes that reward the achieving of a predefined goal in the future is very flexible and effective. Compared with traditional funding tools, prizes reduce the entry barriers and help to mobilise new talents. They can be tailored to complement traditional incentive instruments, such as grants and scholarships, to spark research into problems which are of critical importance to Europe's future (energy security, climate change, ageing society, etc.).
Why is the lack of an alternative to cold-chain technology an issue?
The delivery of vaccines from manufacturer to recipient can take up to 18 months and for most vaccines, the doses must be kept at a constant and cool temperature, above freezing. This requires an unbroken cold-chain which is logistically complicated and expensive. These problems are exacerbated in regions with weak infrastructure, precisely where the need is often greatest. The World Health Organisation estimates that half of all supplied vaccine doses are wasted. Since most of this wastage is caused by an inadequate cold-chain, there is an urgent need for alternatives to, or cost-effective improvements on existing technologies.
Why is the Commission trying to tackle the issue through an inducement prize?
Prizes are a way of bringing fresh ideas to problems which can seem intractable, as they are not prescriptive in terms of the approach to be taken. This form of funding has become popular worldwide thanks in part to private, non-profit organisations, which have delivered impressive proofs of concept of this new tool to spur innovation. The Commission took advice on the definition of the prize objective and its awarding from experts in the field, including from the X-Prize Foundation, the World Health Organisation, the European Centre for Disease Prevention and Control and academia.
Who can apply and how?
Applications for the vaccine technology prize can be submitted over the next year from competitors established as legal entities in the EU and associated countries. The competition is therefore open to the very widest possible selection of potential participants.
Applicants can find the rules for the competition and can register their interest to participate via the website: http://ec.europa.eu/research/health/index_en.html
Who will judge this prize? When will it be awarded?
The winner of the prize will be announced in the last quarter of 2013. Applications will be judged by a panel of high level experts to be announced later in 2012.
The rules for the competition state that the winning proposal must convince the judges that vaccines can be safely transported and stored in field conditions such that they retain their full potency and effectiveness, as well as of course their safety characteristics. Further, the solution should be able to be implemented at reasonable cost. Finally, the proposal should be relevant to a number of vaccines so that the eventual impact would be significant.
Is the Commission already funding research in this area?
By the end of 2012, Research Framework Programmes 6 and 7 will have seen in the region of €400 million allocated to over 100 projects on human vaccine research, in addition to other work, including clinical trials, funded elsewhere in these programmes and of relevance to the field. The majority of projects funded have focused on infectious disease, innovative therapies, public health, development and ageing and span basic research to the development of new vaccines, the improvement of their design or the development of new vaccination strategies. Cold chain technology has not been a focus of FP6 or FP7.
The Commission said it may use prizes in its consultation leading to adoption of the Horizon 2020 proposal. Could they become used more widely?
Inducement prizes will figure more prominently in Horizon 2020 than they did in FP7, but will still form only a small part of the armoury in the fight against infectious disease and other challenges that we face. The Horizon 2020 Communication highlights prizes as a new approach that will encourage the involvement of a wider range of innovators to achieve specific goals.
Why two million euro? It doesn't sound very much compared to some projects financed under FP7?
Extensive consultation with the acknowledged leaders in the field of inducement prizes as well as the abovementioned experts in the field of vaccines resulted in the allocation of €2 million as a prize fund. The goal of the competition is different to vaccine development projects financed under FP7, which frequently involve activities which are cost-intensive, such as clinical trials.
Friday, 28 August 2015Commission speeds up access to market of 16 innovative projects with €36 million
Wednesday, 22 July 2015Investment Plan for Europe: European Fund for Strategic Investments adds firepower to Horizon2020 for innovative SMEs
Thursday, 16 July 2015€100 million to innovative companies in Italy with financial backing from Horizon 2020
Wednesday, 15 July 2015€140 million to innovative companies in the UK with financial backing from Horizon 2020
Monday, 13 July 2015First loan under InnovFin Infectious Diseases provides €10 million to improve HIV monitoring
Friday, 10 July 2015SMEs in Belgium to benefit from €100 million in EU-guaranteed loans
All News Alerts/Press Releases